CRISPR Therapeutics details CTX310 reduction data, names new CTO and CFO
Phase 1a results show deep ANGPTL3, triglyceride and LDL-C reductions as the company names a new technical chief and CFO alongside Q3 results.
FDA, SEC filing (3)
5 stories
Phase 1a results show deep ANGPTL3, triglyceride and LDL-C reductions as the company names a new technical chief and CFO alongside Q3 results.
FDA, SEC filing (3)
Silver, promoted from SVP Finance, becomes CFO effective immediately on October 19, 2026, as Prasad departs for outside opportunities.
SEC filing